Press Release July 11, 2016

PRESS: Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It? (Scrip)

Rob Cerwinski, a partner in Goodwin's IP Litigation Group, and Alexandra Lu, an associate in Goodwin’s Litigation Department, talk about the latest in biosimilar news, including the FDA’s positive review of Sandoz Inc.'s application for its biosimilar version of Enbrel. They also discuss the products heading to the US market and products that are pending agency approval.

Read the full Scrip article here.